NuPathe (NASDAQ: PATH), a Safeguard Scientifics partner company, was acquired by Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) on February 21, 2014 at a price of $3.65 per share.

The company, which became a Safeguard partner in 2011, offers the first commercial patch for the acute treatment of migraines, with a pipeline of additional innovative neuroscience solutions targeting the treatment of Parkinson’s disease, schizophrenia and bipolar disorder.

(Visited 409 times, 1 visits today)